Company: NCEL
Filing Date: 2025-03-31
Form Type: 425
Source: 0001213900-25-025889
Chunk: 4

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: 425
Chunk 4
---
:----|:------------------------------------------------------------------------------------------------------------------------------------------------|
| 99.2        |     | Form of Registration Rights Agreement                                                                                                           |
| 99.3        |     | Common Shares Purchase Agreement, dated March 30, 2025, between NLS Pharmaceutics and the certain purchaser thereto.                            |
| 99.4        |     | Form of Pre-Funded Warrant                                                                                                                      |
| 99.5        |     | Press release titled: “NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement.” |

<div align='center'>3

SIGNATURES</div>

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| Date: March 31, 2025 | NLS Pharmaceutics Ltd. 
 By:                    | /s/ Alexander Zwyer |                         |
|:---------------------|:-----------------------|:--------------------|:------------------------|
|                      |                        | Name:               | Alexander Zwyer         |
|                      |                        | Title:              | Chief Executive Officer |

<div align='center'>4</div>

Exhibit 99.1

<div align='center'>SECURITIES PURCHASE AGREEMENT</div>

This Securities Purchase Agreement
(this “”) is dated as of March 26, 2025, among NLS Pharmaceutics Ltd., a corporation incorporated under the
laws of Switzerland and includes any successor Company thereto (the “”), and each purchaser identified on the
signature pages hereto (each, including its successors and permitted assigns, a “” and collectively the “”).

WHEREAS, the Company and Purchasers
desire to enter into this Agreement, pursuant to which the Purchasers are to be granted the right to acquire securities of the Company
as set forth herein; and

WHEREAS, subject to the terms
and conditions set forth in this Agreement and pursuant to an exemption from the registration requirements of Section 5 of the Securities
Act contained in Section 4(a)(2) thereof and/or Regulation D thereunder, the Company desires to issue and sell to each Purchaser, and
each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in
this Agreement (the “”).

NOW, THEREFORE, IN CONSID